Cullinan Therapeutics Inc

CGEM remains in a Stage 2 advancing trend with a bullish medium-term bias, but the active Bearish Pivot Point indicates early downside mean-reversion risk. Recent price weakness broken below the 9/21 EMAs and a shallow bounce into the 50 DMA suggest unfavorable short-term timing. We recommend waiting for a clear pullback into the rising EMA and 50 DMA support zone before initiating exposure.

• ↑Strong Buy consensus with $30 median price target implies 65.5% upside
• ↑289 funds hold 66.2M shares; bullish 0.37 put/call ratio
• ↓Negative profitability and earnings yield highlight lack of positive cash flow